---
{"dg-publish":true,"permalink":"/usmle/review/monoclonal-antibodies/","tags":["t1"]}
---

- **Rituximab:**
    
    - **Target:** CD20 (B-cells)
    - **Use:** B-cell lymphomas, CLL, rheumatoid arthritis
    - **AE:** Infusion reactions, PML risk, infections
- **Alemtuzumab:**
    
    - **Target:** CD52 (T & B cells, etc.)
    - **Use:** Multiple sclerosis, CLL
    - **AE:** Infusion reactions, infections, **autoimmune disorders (thyroid, ITP)**
- **Trastuzumab (Herceptin):**
    
    - **Target:** HER2/neu
    - **Use:** HER2+ breast & gastric cancer
    - **AE:** **Cardiotoxicity** (heart failure)
- **Infliximab, Adalimumab (Anti-TNF-α):**
    
    - **Target:** TNF-α
    - **Use:** Rheumatoid arthritis, IBD (Crohn's, UC), psoriasis
    - **AE:** **Reactivation of latent TB**, infections
- **Eculizumab:**
    
    - **Target:** Complement C5
    - **Use:** Paroxysmal nocturnal hemoglobinuria (PNH), aHUS
    - **AE:** **Increased risk of _Neisseria meningitidis_ infection** (vaccinate!)
- **Omalizumab:**
    
    - **Target:** IgE
    - **Use:** Allergic asthma, chronic idiopathic urticaria
    - **AE:** Anaphylaxis (rare but serious)
- **Bevacizumab:**
    
    - **Target:** VEGF
    - **Use:** Colorectal cancer, lung cancer, glioblastoma
    - **AE:** Hemorrhage, blood clots, impaired wound healing, GI perforation
- **Denosumab:**
    
    - **Target:** RANKL
    - **Use:** Osteoporosis, bone metastases
    - **AE:** **Hypocalcemia**, osteonecrosis of the jaw (ONJ)
- **Immune Checkpoint Inhibitors (e.g., Pembrolizumab, Nivolumab - anti-PD-1; Ipilimumab - anti-CTLA-4):**
    
    - **Target:** PD-1, PD-L1, or CTLA-4 (release brakes on T-cells)
    - **Use:** Various cancers (melanoma, lung, kidney, etc.)
    - **AE:** **Immune-related adverse events (irAEs)** - colitis, hepatitis, endocrinopathies, pneumonitis

